Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Analyst Moves: BIIB, GEVA

Forbes - 3 Jan 2013 19:38
Biogen Idec (BIIB) was downgraded by Piper Jaffray (PJC) to neutral from overweight, as the share price has been approaching the previously set $168 price target.
Full Article at Forbes

More Market News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard